Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

J Tabernero; E Van Cussem; Y Bang; C Fuchs; L Wyrwicz; K Lee; I Kudaba; M Garrido; C Chung; CC Salguero; W Mansoor; M Braghiroli; E Goekkurt; J Chao; Z Wainberg; U Kher; S Shah; S Karg; K Shitara

doi:10.1093/annonc/mdz183.001

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

J Tabernero
, E Van Cussem
, Y Bang
, C Fuchs
, L Wyrwicz
, K Lee
, I Kudaba
, M Garrido
, C Chung
, CC Salguero
, W Mansoor
, M Braghiroli
, E Goekkurt
, J Chao
, Z Wainberg
, U Kher
, S Shah
, S Karg
, K Shitara

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	152-153
Journal	Annals of Oncology
Volume	30
Issue number	Suppl.4
DOIs	https://doi.org/10.1093/annonc/mdz183.001
Publication status	Published - Jul 2019
Externally published	Yes
Event	European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer - Barcelona, Spain Duration: 3 Jul 2019 → 6 Jul 2019 Conference number: 21 https://www.hmpgloballearningnetwork.com/site/onc/news/esmo-world-congress-gastrointestinal-cancer-2019#:~:text=The%20ESMO%2021st%20World%20Congress,to%20share%20pioneering%20research%2C%20approaches%2C

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1093/annonc/mdz183.001

https://www.annalsofoncology.org/article/S0923-7534(19)30956-1/fulltext

Cite this

Tabernero, J., Van Cussem, E., Bang, Y., Fuchs, C., Wyrwicz, L., Lee, K., Kudaba, I., Garrido, M., Chung, C., Salguero, CC., Mansoor, W., Braghiroli, M., Goekkurt, E., Chao, J., Wainberg, Z., Kher, U., Shah, S., Karg, S., & Shitara, K. (2019). Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Annals of Oncology, 30(Suppl.4), 152-153. https://doi.org/10.1093/annonc/mdz183.001

@article{796830eb90d347c4bf077cecddf05ed9,

title = "Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study",

author = "J Tabernero and \{Van Cussem\}, E and Y Bang and C Fuchs and L Wyrwicz and K Lee and I Kudaba and M Garrido and C Chung and CC Salguero and W Mansoor and M Braghiroli and E Goekkurt and J Chao and Z Wainberg and U Kher and S Shah and S Karg and K Shitara",

year = "2019",

month = jul,

doi = "10.1093/annonc/mdz183.001",

language = "English",

volume = "30",

pages = "152--153",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.4",

note = "European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer ; Conference date: 03-07-2019 Through 06-07-2019",

url = "https://www.hmpgloballearningnetwork.com/site/onc/news/esmo-world-congress-gastrointestinal-cancer-2019\#:\textasciitilde{}:text=The\%20ESMO\%2021st\%20World\%20Congress,to\%20share\%20pioneering\%20research\%2C\%20approaches\%2C",

}

Tabernero, J, Van Cussem, E, Bang, Y, Fuchs, C, Wyrwicz, L, Lee, K, Kudaba, I, Garrido, M, Chung, C, Salguero, CC, Mansoor, W, Braghiroli, M, Goekkurt, E, Chao, J, Wainberg, Z, Kher, U, Shah, S, Karg, S & Shitara, K 2019, 'Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study', Annals of Oncology, vol. 30, no. Suppl.4, pp. 152-153. https://doi.org/10.1093/annonc/mdz183.001

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. / Tabernero, J; Van Cussem, E; Bang, Y et al.
In: Annals of Oncology, Vol. 30, No. Suppl.4, 07.2019, p. 152-153.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

T2 - European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer

AU - Tabernero, J

AU - Van Cussem, E

AU - Bang, Y

AU - Fuchs, C

AU - Wyrwicz, L

AU - Lee, K

AU - Kudaba, I

AU - Garrido, M

AU - Chung, C

AU - Salguero, CC

AU - Mansoor, W

AU - Braghiroli, M

AU - Goekkurt, E

AU - Chao, J

AU - Wainberg, Z

AU - Kher, U

AU - Shah, S

AU - Karg, S

AU - Shitara, K

N1 - Conference code: 21

PY - 2019/7

Y1 - 2019/7

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000475860200447

U2 - 10.1093/annonc/mdz183.001

DO - 10.1093/annonc/mdz183.001

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

SP - 152

EP - 153

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.4

Y2 - 3 July 2019 through 6 July 2019

ER -

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this